Derivative liabilities | 13. Derivative liabilities Warrants issued to common shareholders On January 19, 2023, as part of a share subscription , On February 17, 2023, as part of a share subscription , On April 19, 2023, as part of a share subscription , On June 16, 2023, as part of a share subscription, the Company issued warrants with the option to purchase 3,659 Voting Common Shares of the Company for a period of three years from the grant date at an original exercise price of U.S. $546.75 ($722.25). On August 2, 2023, as part of a share subscription, the Company issued warrants with the option to purchase 3,662 Voting Common Shares of the Company for a period of three years from the grant date at an original exercise price of U.S. $546.75 ($724.95). On September 20, 2023, as part of a share subscription, the Company issued warrants with the option to purchase 2,763 Voting Common Shares of the Company for a period of three years from the grant date at an original exercise price of U.S. $546.75 ($734.40). On December 13, 2023, the Company agreed to reduce the exercise price of 20,358 of its previously issued warrants to U.S. $141.75 ($191.23). For the fiscal year ended August 31, 2024, the Company recorded a loss of $896,458 related to the re-pricing of these instruments in net finance income. The table below lists the assumptions used to determine the fair value of these warrant grants or issuances. Volatility is based on the historical share price volatility of the Company and other public companies with characteristics similar to the Company. Original Risk-free Exercise Market Expected interest Expected price price volatility rate life Issuance date $ $ % % [years] January 19, 2023 760.05 760.05 100 3.4 3 February 17, 2023 765.45 816.75 100 4.0 3 April 19, 2023 761.40 749.25 75 3.9 3 June 16, 2023 722.25 742.50 75 4.1 3 August 2, 2023 724.95 688.50 75 4.8 3 September 20, 2023 734.40 594.00 75 4.8 3 Number of Weighted average Revised warrants remaining Exercise price outstanding contractual life Issuance date $ # [years] January 19, 2023 191.23 4,108 1.14 February 17, 2023 191.23 3,520 1.22 April 19, 2023 191.23 2,826 1.38 June 16, 2023 191.23 3,659 1.54 August 2, 2023 191.23 3,662 1.67 September 20, 2023 191.23 2,763 1.80 As at November 30, 2024, the derivative liabilities related to the warrants issued to common shareholders amounted to nil [August 31, 2024 – $30,564]. For the three-month period ended November 30, 2024, the Company allocated transaction costs of nil related to the warrants issued during the period, which were recorded in net finance income [2023 – $149,472] [note 18] The table below summarizes the movement in the derivative liabilities related to the warrants issued to common shareholders during the three-month period ended November 30, 2024 and the fiscal year ended August 31, 2024: As at As at November 30, August 31, 2024 2024 $ $ Opening balance 30,564 5,558,822 Additions — 765,733 Effect on fair value of repricing of warrants — 896,458 Change in estimate of fair value (30,564) (7,190,449) Closing balance — 30,564 For the three month period ended November 30, 2024, the Company recorded a gain of $30,564 related to the valuation of these instruments in net finance income [2023 – $5,411,168] [ note 18 Series A Convertible Preferred Shares On December 13, 2023, the Company authorized the issuance of Series A Convertible Preferred Shares. This class of shares ranks senior to the Voting Common Shares but retains no voting rights. They have a stated value of US$1,000 per share and are convertible into Voting Common Shares of the Company at the election of the holder at any time at a price of US$141.75 per share, exercise price subject to adjustment. The Series A Convertible Preferred Shares are convertible at the election of its holder into that number of Voting Common Shares determined by dividing its stated value (plus any and all other amounts which may be owing in connection therewith) by the exercise price, subject to certain beneficial ownership limitations which prohibit any holder from converting into an amount of Voting Common Shares that would cause such holder to beneficially own more than 4.99% of the then outstanding Voting Common Shares). On the one-year anniversary of the original issuance date, the Series A Convertible Preferred Shares will automatically convert into Voting Common Shares at the lesser of the then exercise price, and 80% of the average volume-weighted average price of the Company’s Voting Common Shares during the five On December 21, 2023, the Company issued 3,000 Series A Convertible Preferred Shares and 21,169 warrants to purchase Voting Common Shares for a total cash consideration of $4,036,025 (US$3,000,000). For the fiscal year ended August 31, 2024, the Company incurred transaction costs of $615,306 related to this issuance. During the fiscal year ended August 31, 2024, 650 Series A Convertible Preferred Shares were converted into 11,642 Voting Common Shares at a value of $301,997 [ Note 15 On August 16, 2024, 21,169 warrants to purchase Voting Common Shares issued to Series A Convertible Preferred shareholders were exchanged for 41,858 Voting Common Shares and 475 Pre-Funded Warrants [ Note 15 During the three-month period ended November 30, 2024, 400 Series A Convertible Preferred Shares were converted into 9,877 Voting Common Shares at a value of $136,689 [ Note 15 Given the variability associated with the various components of this instrument, these instruments were recorded as derivative liabilities and will be subject to fair value adjustments at the issuance date and at subsequent balance sheet dates. The fair value was determined using the Monte Carlo simulation run under the Geometric Brownian Motion. Since the fair value is based on valuation using unobservable market inputs, the Company did not recognize the loss on initial recognition. The difference between the fair value at initial recognition and the transaction price was deferred and is recognized over time based on the individual terms of each financial instrument. This difference determined was due to delays in negotiations, the changes in the capital market and the Company’s liquidity situation. The table below summarizes the movement in the derivative liabilities related to the Series A Convertible Preferred Shares including the related warrants and option to purchase additional Series A Convertible Preferred Shares and related warrants during the three-month period ended November 30, 2024 and the fiscal year ended August 31, 2024: As at As at November 30, August 31, 2024 2024 $ $ Opening balance 694,232 — Fair value at issuance — 12,744,593 Deferred loss at issuance — (8,737,194) Revaluation at the end of the period (1,217,972) (10,336,357) Amortization of the deferred loss during the period — 7,325,187 Accelerated amortization of the deferred loss during the period 804,676 — Conversion to Voting Common Shares during the period [ Note 19 (136,689) (301,997) Closing balance 144,247 694,232 For the three-month period ended November 30, 2024, the Company recorded a gain of $413,296 related to the valuation of these instruments in net finance income [2023 – nil] [ note 18 Series B Convertible Preferred Shares On December 13, 2023, the Company authorized the issuance of Series B Convertible Preferred Shares. This class of shares ranks senior to the Voting Common Shares but retains no voting rights. They have a stated value of US$1,000 per share and are convertible into Voting Common Shares of the Company at the election of the holder at any time at a price of US$141.75 per share, exercise price subject to adjustment. The Series B Convertible Preferred Shares are convertible at the election of its holder into that number of Voting Common Shares determined by dividing its stated value (plus any and all other amounts which may be owing in connection therewith) by the exercise price, subject to certain beneficial ownership limitations which prohibit any holder from converting into an amount of Voting Common Shares that would cause such holder to beneficially own more than 4.99% of the then outstanding Voting Common Shares). On the one-year anniversary of the original issuance date, the Series B Convertible Preferred Shares will automatically convert into Voting Common Shares at the lesser of the then exercise price, and 80% of the average volume-weighted average price of the Company’s Voting Common Shares during the five On January 17, 2024, the Company issued 3,000 Series B Convertible Preferred Shares and 21,165 warrants to purchase Voting Common Shares for a total cash consideration of $4,044,900 (US$3,000,000). For the fiscal year ended August 31, 2024, the Company incurred transaction costs of $839,195 related to this issuance, which were recorded in net finance income. Given the variability associated with the various components of this instrument, these instruments were recorded as derivative liabilities and will be subject to fair value adjustments at the issuance date and at subsequent balance sheet dates. The fair value was determined using the Monte Carlo simulation run under the Geometric Brownian Motion. Since the fair value is based on valuation using unobservable market inputs, the Company did not recognize the loss on initial recognition. The difference between the fair value at initial recognition and the transaction price was deferred and is recognized over time based on the individual terms of each financial instrument. This difference determined was due to delays in negotiations, the changes in the capital market and the Company’s liquidity situation. The table below summarizes the movement in the derivative liabilities related to the Series B Convertible Preferred Shares including the related warrants during the three-month period ended November 30, 2024 and the fiscal year ended August 31, 2024: As at As at November 30, August 31, 2024 2024 $ $ Opening balance 1,455,594 — Fair value at issuance — 6,888,006 Deferred loss at issuance — (2,841,008) Revaluation at the end of the period (2,019,193) (4,642,780) Amortization of the deferred loss during the period — 1,674,778 Accelerated amortization of the deferred loss during the period 789,633 376,598 Closing balance 226,034 1,455,594 For the three-month period ended November 30, 2024, the Company recorded a gain of $1,229,560 related to the valuation of these instruments in net finance income [2023 – nil] [ note 18 |